Here&There Tim Kempster Kevin Taylor AVA6k will be going head 2 head with Doxorubicin as a 1st line therapy in STS. This is what it has to beat: ORR 18% PFS 6months OS 19 months If you think the trial results to date don’t suggest that AVA6000 has every chance in bettering these then you are a troll #AVCT